Skip to content
Evigrade
MajorMacrolide antibiotic×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

The liver and gut break down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6, and ranolazine is also a substrate of the transporter P-glycoprotein (P-gp) (ranolazine label, US Food and Drug Administration, FDA). According to its summary of product characteristics (SmPC), erythromycin is a moderate inhibitor of CYP3A4 and P-gp (erythromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and the ranolazine documents also class it as a moderate CYP3A4 inhibitor (ranolazine SmPC, European Medicines Agency, EMA; FDA). The documents give no figures for this pair. For comparison, diltiazem, another moderate inhibitor, increased steady-state ranolazine levels 1.5- to 2.4-fold (EMA). Both drugs prolong the QT interval: ranolazine in a concentration-dependent way (EMA), and erythromycin with a risk of torsade de pointes (AEMPS). The European ranolazine SmPC lists erythromycin among drugs that prolong the heart-rate-corrected QT interval (QTc) and states that, in theory, combining such drugs with ranolazine may increase the risk of ventricular arrhythmias (EMA).

Symptoms

QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). QT prolongation with a risk of arrhythmia and torsade de pointes has been seen with macrolides, including erythromycin, and deaths have been reported (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Feeling faint or lightheaded and an irregular or fast heartbeat may be related to QT prolongation (ranolazine label, US Food and Drug Administration, FDA). Dizziness, nausea and vomiting become more frequent as the ranolazine dose rises (ranolazine SmPC, European Medicines Agency, EMA).

Management

Limit ranolazine to 500 mg twice daily in patients taking moderate CYP3A inhibitors. The US ranolazine label names erythromycin among them (ranolazine label, US Food and Drug Administration, FDA). This limit is below the maximum dose in both the US label, 1000 mg twice daily (FDA), and the European summary of product characteristics (SmPC), 750 mg twice daily (ranolazine SmPC, European Medicines Agency, EMA). According to the European SmPC, start ranolazine and increase its dose with caution in patients taking erythromycin, adjust the dose carefully and reduce it if needed. Use ranolazine with caution with drugs that affect the heart-rate-corrected QT interval (QTc) (EMA). Use erythromycin with caution with other QT-prolonging drugs and in coronary artery disease, severe heart failure, conduction disorders or clinically relevant bradycardia. Do not give it to patients with a history of QT prolongation or ventricular arrhythmia, or with low potassium or magnesium (erythromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The SmPC of a Spanish generic intravenous erythromycin contraindicates erythromycin with named groups of QT-prolonging drugs, which do not include ranolazine, and advises extreme caution with other such drugs (intravenous erythromycin SmPC, AEMPS). The US erythromycin label says that dose adjustments of drugs mainly metabolised by CYP3A may be considered (erythromycin FDA label). If dizziness, nausea or vomiting occur, the ranolazine dose may need to be reduced to 500 mg or 375 mg twice daily, and if the symptoms do not resolve, stop ranolazine (EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Erythromycin

Other interactions with Ranolazine